To Receive a Certificate for This Activity:

1. 1. Read the Program Overview on this page.
2. 2. Review the Faculty Biographies, Accreditation Statements, and Disclosure tabs.
3. 3. Access the Activity in full.
4. 4. Complete the Post-Test & Evaluation.
5. 5. A printable certificate will be available immediately following the activity.

Begin Activity

Program Overview

Activity Description

Many people with type 2 diabetes are not able to achieve blood glucose targets with oral noninsulin medications alone. For these patients, exogenous insulin therapy is essential for preventing diabetes-related complications. Diabetes management has been significantly advanced by the development of insulin analogues, which are synthetic preparations that resolve some of the pharmacokinetic limitations and adherence barriers of conventional human insulin therapies. Novel premixed insulin analogues, which require only 1 or 2 daily injections, are designed to control both fasting and prandial glucose excursions.

Until recently, no comprehensive study had been conducted on the benefits and harms of premixed insulin analogues versus other insulin therapies and noninsulin oral antidiabetic agents. In 2008, a comparative effectiveness review on this topic was published with support from the Agency for Healthcare Research and Quality (AHRQ). This educational activity – featuring the first author of the AHRQ systematic review and a leading nurse practitioner who specializes in diabetes care – presents an engaging case-based discussion about the review findings and their potential applications in clinical practice.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Summarize the major findings from AHRQ's systematic review on the comparative effectiveness of premixed insulin analogues for adults with type 2 diabetes
• Explain the tradeoffs in benefits versus harms for premixed insulin analogues, other insulin preparations, and noninsulin antidiabetic drugs
• Demonstrate effective strategies for communicating comparative effectiveness research findings to patients
• Apply AHRQ's systematic review findings to educating patients about options for insulin therapies and to making patient-centered treatment and management decisions

Target Audience

This CME activity is designed to meet the educational needs of physicians, nurse practitioners, pharmacists, nurses, dieticians, medical assistants, health education specialists.

Method of Participation

To receive a certificate for this activity, you should:

• Complete the learner assessment pretest
• View the entire activity online (Hardware/Software Requirements: Broadband & Flash Player or HTML5 browser)
• Complete an online evaluation & post-test
• Print your certificate online

The estimated time to complete this activity, including review of the materials, is 1.0 hour.

Term of Approval

March 31, 2011 through March 30, 2013. Original release date: March 31, 2011

Acknowledgement of Support

There is no fee for this CME/CE activity. This activity is sponsored by PRIME Education, Inc (PRIME^®) and funded under contract HHSA290201000006G from the Agency for Healthcare Research and Quality (AHRQ), U.S. Department of Health and Human Services (HHS).

Faculty Biographies and Disclosures

Accreditation/Credit Designation

Physician Credit Designation Statement

PRIME Education, Inc. (PRIME^®) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

PRIME^® designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Physician Assistant Accreditation Statement

AAPA accepts AMA Category 1 CME Credit^™ for the PRA from organizations accredited by ACCME.

Nurse Practitioner Accreditation Statement

PRIME Education, Inc. (PRIME^®) is accredited by the American Academy of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 060815. This program is accredited for 1.0 contact hour. Program ID# CER2.

This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards.

Pharmacist Accreditation Statement

This curriculum has been approved for 1.0 contact hour by PRIME^®. PRIME^® is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Universal Activity Number for this program is 0255-0000-11-005-H01-P. This learning activity is Knowledge-Based.

Nurse Accreditation Statement

PRIME Education, Inc. (PRIME^®) is an Approved Provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

PRIME^® designates this activity for 1.0 contact hour.

Case Manager Accreditation Statement

The Commission for Case Manager Certification designates this educational activity for 1.0 contact hour for certified case managers.

Medical Assistant Accreditation Statement

This program has been granted prior approval by the American Association of Medical Assistants (AAMA) for 1.0 Continuing Education unit. Approval #121745. Granting approval in no way constitutes endorsement by the AAMA of the program content or the program's sponsor.

Dietician Accreditation Statement

This program has been approved by the Commission on Dietetic Registration for 1.0 CPEUs of continuing education for Registered Dieticians (RD) and Dietetic Technicians, Registered (DTR).

Certified Health Education Specialist Accreditation Statement

Sponsored by PRIME Education, Inc. (PRIME^®), a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc.

This program is designated for Certified Health Education Specialists (CHES) to receive up to 1.0 Category I contact hours in health education.

CHES Provider Number: SSP3577

Faculty Disclosures

Disclosure Policy

PRIME Education Inc (PRIME^®) endorses the standards of the ACCME, as well as those of the AANP, ANCC and ACPE, that require everyone in a position to control the content of a CME/CE activity to disclose all financial relationships with commercial interests that are related to the content of the CME/CE activity. CME/CE activities must be balanced, independent of commercial bias and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

Aconflict of interest is created when individuals in a position to control the content of CME/CE have a relevant financial relationship with a commercial interest which therefore may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks or other financial benefits.

PRIME willidentify, review and resolve all conflicts of interest that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff are provided with this activity.

Presentations that provide information in whole or in part related to non FDA approved uses of drugs and/or devices will disclose the unlabeled indications or the investigational nature of their proposed uses to the audience. Participants should refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. Participants should verify all information and data before treating patients or employing any therapies prescribed in this educational activity. The opinions expressed in the educational activity are those of the presenting faculty and do not necessarily represent the views of PRIME^®, the ACCME, AANP, ACPE, ANCC and other relevant accreditation bodies.

Content validation methods are consistently utilized by PRIME to ensure that all program content is evidence-based, fair-balanced, and developed with scientific rigor and integrity. All clinical recommendations are based on evidence accepted within the medical profession. All scientific research referred to, reported or used to support a clinical recommendation conforms to accepted standards of experimental design, data collection and analysis. In addition to review of content by course directors and expert faculty, content is also validated through independent peer reviewers selected for their expertise in the content area, as well as their experience in the intended audience. All peer reviewers, planners, course directors, faculty and relevant staff utilized by PRIME complete disclosures which are related to their role in the educational activity.

Accessibility

PRIME^®is committed to providing access to our CME programs for individuals with disabilities as identified in Section 508 of the Rehabilitation Act for all web-based programs. This website is 508 compliant.

Post-Test & Evaluation

You must access the activity before receiving credit!